MCID: THY122
MIFTS: 59

Thyroid Gland Cancer

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Thyroid Gland Cancer

MalaCards integrated aliases for Thyroid Gland Cancer:

Name: Thyroid Gland Cancer 12
Malignant Neoplasm of Thyroid Gland 12 33
Neoplasm of the Thyroid Gland 29 6
Thyroid Neoplasms 55 44
Thyroid Neoplasm 12 17
Malignant Tumour of Thyroid Gland 12
Head and Neck Cancer, Thyroid 12
Neoplasm of Thyroid Gland 12
Thyroid Gland Carcinoma 12
Thyroid Gland Neoplasm 12
Thyroid Carcinomas 15
Thyroid Carcinoma 15
Thyroid Cancers 15
Thyroid Cancer 15

Classifications:



External Ids:

Disease Ontology 12 DOID:1781 DOID:3963
ICD9CM 35 193
MeSH 44 D013964
SNOMED-CT 68 94098005
ICD10 33 C73
UMLS 72 C0007115 C0040136 C0549473

Summaries for Thyroid Gland Cancer

Disease Ontology : 12 An endocrine gland cancer located in the thryoid gland located in the neck below the thyroid cartilage.

MalaCards based summary : Thyroid Gland Cancer, also known as malignant neoplasm of thyroid gland, is related to thyroid carcinoma, hurthle cell and struma ovarii. An important gene associated with Thyroid Gland Cancer is RET (Ret Proto-Oncogene), and among its related pathways/superpathways are Regulation of lipid metabolism Insulin signaling-generic cascades and Focal Adhesion. The drugs Betamethasone and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lymph node and breast, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Thyroid Gland Cancer

Diseases related to Thyroid Gland Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1119)
# Related Disease Score Top Affiliating Genes
1 thyroid carcinoma, hurthle cell 35.4 TG MALAT1
2 struma ovarii 32.3 TG RET BRAF
3 differentiated thyroid carcinoma 32.2 TG RET PAX8 NRAS KRAS HRAS
4 pituitary adenoma 31.9 MALAT1 HOTAIR H19
5 ovarian germ cell teratoma 31.9 TG RET NRAS
6 malignant struma ovarii 31.9 TG RET NRAS HRAS
7 mature teratoma 31.8 TG KRAS BRAF
8 multinodular goiter 31.8 TG PAX8 HRAS
9 squamous cell carcinoma, head and neck 31.7 PIK3CA HRAS HOTAIR H19 GAS5 BRAF
10 neurofibromatosis, type iv, of riccardi 31.6 RET HRAS CDKN2B-AS1
11 thyroid cancer, nonmedullary, 1 31.5 PVT1 PTCSC3 MALAT1 HOTAIR H19 GAS5
12 leukemia, chronic lymphocytic 31.5 NRAS KRAS HRAS BRAF
13 laryngeal squamous cell carcinoma 31.5 MALAT1 HOTAIR H19 CDKN2B-AS1
14 renal cell carcinoma, papillary, 1 31.5 PIK3CA PAX8 NRAS HRAS BRAF
15 glioblastoma 31.5 PIK3CA NRAS MALAT1 HRAS HOTAIR H19
16 benign struma ovarii 31.4 TG RET NRAS HRAS
17 leukemia, chronic myeloid 31.4 UCA1 NRAS HRAS HOTAIR H19
18 osteogenic sarcoma 31.4 UCA1 PVT1 PANDAR MALAT1 HOTAIR H19
19 thyroid cancer, nonmedullary, 2 31.3 TG RET PIK3CA PAX8 NRAS HRAS
20 kidney cancer 31.3 PVT1 MALAT1 HOTAIR H19 GAS5
21 papillary carcinoma 31.3 TG RET PAX8 BRAF
22 adenocarcinoma 31.3 RET PIK3CA MALAT1 KRAS HRAS H19
23 esophageal cancer 31.3 UCA1 PVT1 PIK3CA MALAT1 KRAS HRAS
24 thyroid carcinoma, familial medullary 31.3 TG RET MALAT1 KRAS
25 giant congenital nevus 31.3 NRAS HRAS
26 thyroid gland disease 31.2 TG RET PAX8
27 adrenocortical carcinoma, hereditary 31.2 PIK3CA NRAS H19 BRAF
28 follicular adenoma 31.2 TG RET PAX8
29 colonic disease 31.2 RET KRAS HRAS
30 malignant glioma 31.2 PVT1 HOTAIR GAS5 CDKN2B-AS1
31 sarcoma 31.2 PIK3CA KRAS HRAS HOTAIR BRAF
32 endometrial cancer 31.2 UCA1 PIK3CA PAX8 KRAS HRAS HOTAIR
33 lung cancer 31.2 UCA1 PVT1 PIK3CA PANDAR NRAS MALAT1
34 myeloma, multiple 31.2 UCA1 PVT1 NRAS MALAT1 KRAS HRAS
35 ovary adenocarcinoma 31.2 PIK3CA KRAS HRAS
36 gastric cancer 31.1 UCA1 PVT1 PIK3CA PANDAR MALAT1 KRAS
37 fetal adenoma 31.1 TG NRAS HRAS
38 glioma 31.1 UCA1 PVT1 PTCSC3 PIK3CA MALAT1 HOTAIR
39 renal cell carcinoma, nonpapillary 31.1 UCA1 PVT1 PAX8 PANDAR MALAT1 HOTAIR
40 melanoma, cutaneous malignant 1 31.1 PIK3CA NRAS HRAS BRAF
41 brain cancer 31.1 PIK3CA NRAS HRAS BRAF
42 endocrine gland cancer 31.1 TG RET PAX8 KRAS HRAS
43 erdheim-chester disease 31.1 PIK3CA NRAS BRAF
44 breast cancer 31.1 UCA1 PVT1 PIK3CA PANDAR MALAT1 KRAS
45 ovarian serous cystadenocarcinoma 31.1 PIK3CA NRAS HRAS BRAF
46 acneiform dermatitis 31.1 PIK3CA NRAS KRAS HRAS
47 bladder cancer 31.1 UCA1 PVT1 PANDAR MALAT1 LINC00312 KRAS
48 pancreatic cancer 31.0 UCA1 PVT1 PIK3CA MALAT1 KRAS HRAS
49 ovarian germ cell cancer 31.0 TG RET
50 leukemia, acute myeloid 31.0 UCA1 NRAS MALAT1 KRAS HRAS HOTAIR

Graphical network of the top 20 diseases related to Thyroid Gland Cancer:



Diseases related to Thyroid Gland Cancer

Symptoms & Phenotypes for Thyroid Gland Cancer

GenomeRNAi Phenotypes related to Thyroid Gland Cancer according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.34 HRAS KRAS PIK3CA BRAF
2 Decreased viability GR00106-A-0 10.34 KRAS
3 Decreased viability GR00221-A-1 10.34 HRAS KRAS NRAS PIK3CA RET
4 Decreased viability GR00221-A-2 10.34 HRAS KRAS PIK3CA RET
5 Decreased viability GR00221-A-3 10.34 HRAS NRAS
6 Decreased viability GR00221-A-4 10.34 PIK3CA RET BRAF
7 Decreased viability GR00231-A 10.34 RET
8 Decreased viability GR00301-A 10.34 KRAS RET BRAF
9 Decreased viability GR00381-A-1 10.34 KRAS BRAF
10 Decreased viability GR00402-S-2 10.34 HRAS KRAS NRAS PIK3CA RET BRAF
11 Increased cell migration GR00055-A-3 8.92 BRAF HRAS KRAS PIK3CA

MGI Mouse Phenotypes related to Thyroid Gland Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 BRAF HRAS KRAS NRAS PIK3CA RET

Drugs & Therapeutics for Thyroid Gland Cancer

DrugBank drugs 16 :

# Drug Name Indication DrugBank ID
1 Iodide I-131 Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. DB09293
2 Liothyronine Liothyronine is officially approved for the following indications: - Replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. - As an adjunct therapy to surgery and radioiodine in the management of thyroid cancer. - As a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomy.[FDA label] In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.[T457] The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy.[T457] Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.[FDA label] DB00279
3 Sunitinib For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate. DB01268
4 Thyrotropin alfa For detection of residueal or recurrent thyroid cancer DB00024

Drugs for Thyroid Gland Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 411)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
4
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
5
Acetaminophen Approved Phase 4 103-90-2 1983
6
Codeine Approved, Illicit Phase 4 76-57-3 5284371
7
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
8
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
9
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
10 Anti-Asthmatic Agents Phase 4
11 Betamethasone-17,21-dipropionate Phase 4
12 Betamethasone Valerate Phase 4 2152-44-5
13 Betamethasone sodium phosphate Phase 4
14 Betamethasone acetate Phase 4
15 Betamethasone benzoate Phase 4
16 Adjuvants, Anesthesia Phase 4
17 Analgesics Phase 4
18 Analgesics, Non-Narcotic Phase 4
19 Respiratory System Agents Phase 4
20 Narcotics Phase 4
21 Analgesics, Opioid Phase 4
22 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
23 Antipyretics Phase 4
24 Antitussive Agents Phase 4
25
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
26
Glucagon Approved Phase 3 16941-32-5
27
Cinacalcet Approved Phase 3 226256-56-0 156419
28
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
29 Gastrointestinal Agents Phase 3
30 Calcium, Dietary Phase 3
31 Autonomic Agents Phase 3
32 Sympathomimetics Phase 3
33 Adrenergic beta-Agonists Phase 3
34 Mydriatics Phase 3
35 Vasoconstrictor Agents Phase 3
36 Bronchodilator Agents Phase 3
37 Fibrin Tissue Adhesive Phase 3
38 Coagulants Phase 3
39 Glucagon-Like Peptide 1 Phase 3
40 Calcimimetic Agents Phase 3
41 insulin Phase 3
42 Insulin, Globin Zinc Phase 3
43
Apatinib Phase 3 811803-05-1
44
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
45
leucovorin Approved Phase 2 58-05-9 143 6006
46
Loperamide Approved Phase 1, Phase 2 53179-11-6 3955
47
Somatostatin Approved, Investigational Phase 2 38916-34-6, 51110-01-1 53481605
48
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
49
Indinavir Approved Phase 2 150378-17-9 5362440
50
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837

Interventional clinical trials:

(show top 50) (show all 645)
# Name Status NCT ID Phase Drugs
1 The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer Unknown status NCT01915485 Phase 4
2 Total Thyroidectomy With Harmonic Scalpel® Versus Standard Surgery. Open Multicentric Randomized Controlled Trial Unknown status NCT00385983 Phase 4
3 Open-Label, Multi-Center, Randomized, Active-Controlled, Phase 4 Study of rAd-p53 Gene Mono-Therapy, With Concurrent Radioactive Iodine , or Combination With Surgery in Subjects With Advanced Malignant Thyroid Tumors Unknown status NCT00902122 Phase 4 rAd-p53 gene;p53 gene therapy
4 Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
5 A Dosimetry Study of Radioiodine (131-I) Uptake Following the Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal Completed NCT00001730 Phase 4 Thyrogen
6 Dose-dependent Effect of Fentanyl on Cough Attenuation During Emergence From General Anaesthesia Completed NCT01308320 Phase 4 fentanyl citrate;saline
7 Is it Possible to Increase Quality of Life, Using Recombinant TSH Instead of Withdrawal of Thyroid Hormone Treatment, Before Iodine Uptake in Patients With Thyroid Cancer? Completed NCT00604318 Phase 4 rhTSH
8 Is the Routine Pressure Dressing After Thyroidectomy Necessary? A Prospective Randomized Controlled Study Completed NCT00400465 Phase 4
9 Prospective Single Arm Post Marketing Phase IV Study to Assess the Safety and Efficacy of Lenvatinib in Subjects With Locally Recurrent or Metastatic, Progressive, Radioiodine Refractory Differentiated Thyroid Cancer Recruiting NCT03573960 Phase 4 Lenvatinib
10 A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients Recruiting NCT01896479 Phase 4 Cabozantinib (XL184) 140 mg;Cabozantinib (XL184) 60 mg;Placebo tablet;Placebo capsule
11 Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery Recruiting NCT03469310 Phase 4 Acetaminophen 500Mg Cap;Tylenol #3 Oral Tablet;Tramadol
12 An International, Randomised, Double-Blind, Two-Arm Study To Evaluate The Safety And Efficacy Of Vandetanib 150 And 300mg/Day In Patients With Unresectable Locally Advanced Or Metastatic Medullary Thyroid Carcinoma With Progressive Or Symptomatic Disease Active, not recruiting NCT01496313 Phase 4 300mg vandetanib;150mg vandetanib
13 Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT02946918 Phase 4 Levothyroxine
14 Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment Not yet recruiting NCT03969108 Phase 4 Indocyanine Green
15 Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter Withdrawn NCT02329379 Phase 4 Levothyroxine
16 Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients - Estimabl Unknown status NCT00435851 Phase 3 Thyrogen, thyroid hormone withdrawal, iode 131
17 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
18 Medico-economic Evaluation Comparing the Use of Ultrasonic Scissors to the Conventional Techniques of Haemostasis in Thyroid Surgery by Cervicotomy Unknown status NCT01551914 Phase 3
19 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
20 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031) Completed NCT02586350 Phase 2, Phase 3 Anlotinib;Placebo
21 Prophylactic Central Lymph Node Dissection in Papillary Thyroid Microcarcinoma: A Prospective Randomized Controlled Trial Completed NCT00795782 Phase 3
22 Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study Completed NCT01616316 Phase 2, Phase 3
23 Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy Completed NCT02112370 Phase 3 Ropivacaine with epinephrine injection
24 A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer Completed NCT01843062 Phase 3 Selumetinib;Placebo;Radioactive Iodine Therapy
25 Decision Aid on Radioactive Iodine Treatment for Early Stage Papillary Thyroid Cancer (Randomized Controlled Trial) Completed NCT01083550 Phase 2, Phase 3
26 Efficacy of Fibrin Sealant to Reduce the Amount of Postoperative Drain in Patients With Harmonic Scalpel-assisted Total Thyroidectomy With Anterior Compartment Neck Dissections Completed NCT01126060 Phase 3 Usage of Fibrin sealant
27 A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed NCT00984282 Phase 3 Sorafenib (Nexavar, BAY43-9006);Placebo
28 Follow-up of Thyroid Cancer Patients From Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method. Completed NCT00295763 Phase 3 Thyrogen (thyrotropin alfa for injection)
29 The Role of Sentinel Lymph Node Biopsy (SLNB) In the Management of Differentiated Thyroid Cancer Completed NCT00794053 Phase 3
30 Phase 3 Trial of Adjuvant External Beam Radiotherapy for Locally Invasive Differentiated Thyroid Carcinoma Completed NCT00144079 Phase 3
31 A Randomized, Controlled, Open-Label, Multi-National Pilot Study of Thyroid Remnant Ablation Comparing the Safety and Ablation Rate Following 131I Administration Using Thyrogen® Versus the Safety and Ablation Rate Following 131I Administration in the Hypothyroid State Completed NCT00196729 Phase 3 Thyrogen + Radioiodine (131I)
32 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer Completed NCT01321554 Phase 3 Lenvatinib;Placebo;Lenvatinib
33 A Phase I/II, Phase III and Extended Phase III Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer Completed NCT00123760 Phase 2, Phase 3
34 Cinacalcet Actions in Familial Primary Hyperparathyroidism Completed NCT00325104 Phase 3
35 Liraglutide in the Treatment of Type 1 Diabetes Mellitus Completed NCT01722266 Phase 3 Liraglutide;Placebo
36 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy Recruiting NCT03690388 Phase 3 Cabozantinib;Placebo
37 Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
38 A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 3 Trial of Donafenib in 131IRefractory Differentiated Thyroid Cancer Recruiting NCT03602495 Phase 3 Donafenib;Placebo
39 A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer Recruiting NCT03048877 Phase 3 Apatinib Oral Tablet;Placebo Oral Tablet
40 Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients? Recruiting NCT01837745 Phase 3 rhTSH stimulation;I131
41 Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study Recruiting NCT01149161 Phase 2, Phase 3
42 Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients Active, not recruiting NCT02418247 Phase 2, Phase 3 I131;I123
43 A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032) Active, not recruiting NCT02586337 Phase 2, Phase 3 Anlotinib;Placebo
44 An International, Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMATM) Versus Placebo in Subjects With Unresectable Locally Advanced or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00410761 Phase 3 ZD6474 (Vandetanib)
45 An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer Active, not recruiting NCT00704730 Phase 3 XL184;Placebo
46 A Randomized,Int.,Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic MTC Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib Active, not recruiting NCT01298323 Phase 3 Vandetanib
47 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China Active, not recruiting NCT02966093 Phase 3 Lenvatinib;Placebo
48 Multicentre Randomised Trial of High Dose Versus Low Dose Radioiodine, With or Without Recombinant Human Thyroid Stimulating Hormone, for Remnant Ablation Following Surgery for Differentiated Thyroid Cancer [HILO] Active, not recruiting NCT00415233 Phase 3
49 A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy. Active, not recruiting NCT01876784 Phase 3 Vandetanib (SAR390530);Placebo
50 Effect of the Radioiodine Dose in Thyroid Ablation- A Randomized Comparison of 1110 MBq to 3700 MBq Active, not recruiting NCT00115895 Phase 3 Radioactive iodine

Search NIH Clinical Center for Thyroid Gland Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Interferon Alfa-2b
Iodide I-131
lenvatinib
levothyroxine
Levothyroxine Sodium
liothyronine
Liothyronine
liothyronine sodium
sorafenib
Sunitinib
Thyroglobulin
THYROID (BEEF)
thyroid (USP)
THYROID PWDR
thyrotropin alfa
Thyrotropin alfa
Vandetanib

Cochrane evidence based reviews: thyroid neoplasms

Genetic Tests for Thyroid Gland Cancer

Genetic tests related to Thyroid Gland Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of the Thyroid Gland 29

Anatomical Context for Thyroid Gland Cancer

MalaCards organs/tissues related to Thyroid Gland Cancer:

41
Thyroid, Lymph Node, Breast, Lung, Bone, Testes, Prostate

Publications for Thyroid Gland Cancer

Articles related to Thyroid Gland Cancer:

(show top 50) (show all 1609)
# Title Authors PMID Year
1
Expression of thyroid transcription factor-1 in colorectal carcinoma. 9 38
20042854 2010
2
Thioredoxin and thioredoxin reductase expression in thyroid cancer depends on tumour aggressiveness. 9 38
20392995 2010
3
Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy. 9 38
19826479 2009
4
Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. 9 38
19506552 2009
5
The significance of Galectin-3 expression in the immunocytochemical evaluation of thyroid fine needle aspiration cytology. 9 38
18415710 2008
6
Differentiating alternative splice variant patterns of human telomerase reverse transcriptase in thyroid neoplasms. 9 38
18816183 2008
7
ECM1 expression in thyroid tumors--a comparison of real-time RT-PCR and IHC. 9 38
18374945 2008
8
Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. 9 38
18246044 2008
9
Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. 9 38
18299472 2008
10
Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. 9 38
18059234 2007
11
Paraganglioma of the thyroid: report of a male case with ultrasonographic imagings, cytologic, histologic, and immunohistochemical features. 9 38
17614779 2007
12
Association of nuclear, cytoplasmic expression of galectin-3 with beta-catenin/Wnt-pathway activation in thyroid carcinoma. 9 38
17515507 2007
13
Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma. 9 38
16798934 2007
14
Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study: evidence of thymic differentiation and solid cell nest origin. 9 38
16861971 2006
15
CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma. 9 38
16889486 2006
16
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. 9 38
17001889 2006
17
[Comparison of CD15, galectin-3 and HBME-1 expression in follicular thyroid neoplasms]. 9 38
17006830 2006
18
Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. 9 38
16688775 2006
19
Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. 9 38
16722927 2006
20
Diagnostic and prognostic value of cell-cycle regulatory genes in malignant thyroid neoplasms. 9 38
16547620 2006
21
Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. 9 38
16405677 2006
22
Diagnostic and prognostic value of angiogenesis-modulating genes in malignant thyroid neoplasms. 9 38
16360397 2005
23
Cyclin D1 expression in primary thyroid carcinomas. 9 38
16380680 2005
24
Galectin-3 immunodetection in follicular thyroid neoplasms: a prospective study on fine-needle aspiration samples. 9 38
16251880 2005
25
ECM1 and TMPRSS4 are diagnostic markers of malignant thyroid neoplasms and improve the accuracy of fine needle aspiration biopsy. 9 38
16135921 2005
26
Quantitative assessment of promoter methylation profiles in thyroid neoplasms. 9 38
15840741 2005
27
Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. 9 38
15947105 2005
28
Telomerase activity in thyroid neoplasms evaluated by the expression of human telomerase reverse transcriptase (hTERT). 9 38
15816620 2005
29
Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. 9 38
15500653 2004
30
PAX8 and peroxisome proliferator-activated receptor gamma 1 gene expression status in benign and malignant thyroid tissues. 9 38
15362967 2004
31
BRAF T1796A transversion mutation in various thyroid neoplasms. 9 38
15001635 2004
32
Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. 9 38
14996725 2004
33
S100A4 expression is an early event of papillary carcinoma of the thyroid. 9 38
15713996 2004
34
Maspin expression is directly associated with biological aggressiveness of thyroid carcinoma. 9 38
15009909 2004
35
Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. 9 38
12964023 2003
36
Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland. 9 38
12657934 2003
37
Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. 9 38
12618337 2003
38
Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions. 9 38
15179758 2003
39
Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. 9 38
12364477 2002
40
Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. 9 38
12481939 2002
41
Utility of thyroid transcription factor-1 and cytokeratin 20 in identifying the origin of metastatic carcinomas of cervical lymph nodes. 9 38
12172048 2002
42
Expression of thyroid transcription factor-1 in strumal carcinoid and struma ovarii: an immunohistochemical study. 9 38
12167104 2002
43
P63 expression in papillary and anaplastic carcinomas of the thyroid gland: lack of an oncogenetic role in tumorigenesis and progression. 9 38
12234063 2002
44
Cytoplasmic accumulation of alpha-catenin in thyroid neoplasms. 9 38
11400246 2001
45
[Tumor markers for endocrine neoplasms]. 9 38
11329795 2001
46
Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas. 9 38
11740048 2001
47
Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms. 9 38
10981870 2000
48
Assessment of ret/PTC-1 rearrangements in neoplastic thyroid tissue using TaqMan RT-PCR. 9 38
10951397 2000
49
Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. 9 38
10821488 2000
50
Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. 9 38
10757334 2000

Variations for Thyroid Gland Cancer

ClinVar genetic disease variations for Thyroid Gland Cancer:

6 (show all 41)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 KRAS NM_004985.5(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
2 KRAS NM_004985.5(KRAS): c.38G> A (p.Gly13Asp) single nucleotide variant Pathogenic rs112445441 12:25398281-25398281 12:25245347-25245347
3 KRAS NM_004985.5(KRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic rs121913535 12:25398282-25398282 12:25245348-25245348
4 KRAS NM_004985.5(KRAS): c.35G> A (p.Gly12Asp) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
5 KRAS NM_004985.5(KRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs121913529 12:25398284-25398284 12:25245350-25245350
6 KRAS NM_004985.5(KRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
7 HRAS NM_005343.4(HRAS): c.35G> T (p.Gly12Val) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
8 RET NM_020630.5(RET): c.2753T> C (p.Met918Thr) single nucleotide variant Pathogenic rs74799832 10:43617416-43617416 10:43121968-43121968
9 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
10 KRAS NM_004985.5(KRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic rs1057519725 12:25378561-25378561 12:25225627-25225627
11 KRAS NM_004985.5(KRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic rs121913238 12:25380277-25380277 12:25227343-25227343
12 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
13 BRAF NM_004333.6(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic rs121913364 7:140453134-140453134 7:140753334-140753334
14 RET NM_020630.5(RET): c.1902C> G (p.Cys634Trp) single nucleotide variant Pathogenic rs77709286 10:43609950-43609950 10:43114502-43114502
15 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
16 HRAS NM_005343.4(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 11:534286-534286 11:534286-534286
17 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
18 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
19 KRAS NM_004985.5(KRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic rs121913240 12:25380276-25380276 12:25227342-25227342
20 KRAS NM_004985.5(KRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs121913240 12:25380276-25380276 12:25227342-25227342
21 KRAS NM_004985.5(KRAS): c.37G> A (p.Gly13Ser) single nucleotide variant Pathogenic rs121913535 12:25398282-25398282 12:25245348-25245348
22 KRAS NM_004985.5(KRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs121913240 12:25380276-25380276 12:25227342-25227342
23 NRAS NM_002524.5(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
24 HRAS NM_005343.4(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 11:534286-534286 11:534286-534286
25 KRAS NM_004985.5(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 12:25398285-25398285 12:25245351-25245351
26 BRAF NM_004333.6(BRAF): c.1802A> C (p.Lys601Thr) single nucleotide variant Pathogenic/Likely pathogenic rs397507484 7:140453133-140453133 7:140753333-140753333
27 PIK3CA NM_006218.4(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 3:178917478-178917478 3:179199690-179199690
28 HRAS ; LRRC56 NM_005343.4(HRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 11:534289-534289 11:534289-534289
29 KRAS NM_004985.5(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 12:25380275-25380275 12:25227341-25227341
30 PIK3CA NM_006218.4(PIK3CA): c.3129G> A (p.Met1043Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913283 3:178952074-178952074 3:179234286-179234286
31 BRAF NM_004333.6(BRAF): c.1803A> C (p.Lys601Asn) single nucleotide variant Likely pathogenic rs121913365 7:140453132-140453132 7:140753332-140753332
32 HRAS NM_005343.4(HRAS): c.183G> T (p.Gln61His) single nucleotide variant Likely pathogenic rs121913496 11:533873-533873 11:533873-533873
33 KRAS NM_004985.5(KRAS): c.38G> T (p.Gly13Val) single nucleotide variant drug response rs112445441 12:25398281-25398281 12:25245347-25245347
34 HRAS NM_005343.4(HRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Likely pathogenic rs121913233 11:533874-533874 11:533874-533874
35 PIK3CA NM_006218.4(PIK3CA): c.3127A> T (p.Met1043Leu) single nucleotide variant Likely pathogenic rs1057519936 3:178952072-178952072 3:179234284-179234284
36 PIK3CA NM_006218.4(PIK3CA): c.3128T> C (p.Met1043Thr) single nucleotide variant Likely pathogenic rs1057519937 3:178952073-178952073 3:179234285-179234285
37 PIK3CA NM_006218.4(PIK3CA): c.3127A> G (p.Met1043Val) single nucleotide variant Likely pathogenic rs1057519936 3:178952072-178952072 3:179234284-179234284
38 HRAS ; LRRC56 NM_005343.4(HRAS): c.181C> G (p.Gln61Glu) single nucleotide variant Likely pathogenic rs28933406 11:533875-533875 11:533875-533875
39 HRAS ; LRRC56 NM_005343.4(HRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Likely pathogenic rs121913233 11:533874-533874 11:533874-533874
40 HRAS ; LRRC56 NM_005343.4(HRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Likely pathogenic rs121913233 11:533874-533874 11:533874-533874
41 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Uncertain significance rs121434592 14:105246551-105246551 14:104780214-104780214

Copy number variations for Thyroid Gland Cancer from CNVD:

7 (show all 22)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48476 11 1 43400000 Gain Thyroid cancer
2 75266 13 18400000 72100000 Loss Thyroid cancer
3 80538 13 93800000 114142980 Loss Thyroid cancer
4 85051 14 37800000 43500000 Copy number FOXA1 Thyroid cancer
5 96631 15 90931472 91045475 Amplificationlicatio n IQGAP1 Thyroid cancer
6 111285 17 35400000 68400000 Gain Thyroid cancer
7 120295 18 23300000 71300000 Loss Thyroid cancer
8 150420 20 1 27100000 Amplification Thyroid cancer
9 151957 20 27100000 62435964 Amplification Thyroid cancer
10 153452 20 37100000 62435964 Gain Thyroid cancer
11 171643 3 170900000 182700000 Gain PIK3CA Thyroid cancer
12 171644 3 170900000 182700000 Gain PIK3CA Thyroid cancer
13 191662 5 1 45800000 Amplification Thyroid cancer
14 191664 5 1 45800000 Gain Thyroid cancer
15 200481 5 55800000 180857866 Gain Thyroid cancer
16 201091 5 65300000 159900000 Amplification Thyroid cancer
17 217036 7 1 158821424 Amplification Thyroid cancer
18 230743 8 1 19100000 Loss Thyroid cancer
19 236403 8 16100000 117700000 Amplification Thyroid cancer
20 236404 8 16100000 146274826 Gain Thyroid cancer
21 261707 X 24900000 59500000 Loss Thyroid cancer
22 303365 21 26028751 26066642 Deletion NRF2 Thyroid cancer

Expression for Thyroid Gland Cancer

Search GEO for disease gene expression data for Thyroid Gland Cancer.

Pathways for Thyroid Gland Cancer

Pathways related to Thyroid Gland Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.94 PIK3CA NRAS KRAS HRAS BRAF
2
Show member pathways
12.93 PIK3CA NRAS KRAS HRAS BRAF
3
Show member pathways
12.92 PIK3CA NRAS KRAS HRAS BRAF
4
Show member pathways
12.9 PIK3CA NRAS KRAS HRAS BRAF
5
Show member pathways
12.86 PIK3CA NRAS KRAS HRAS BRAF
6
Show member pathways
12.81 PIK3CA NRAS KRAS HRAS BRAF
7
Show member pathways
12.78 PIK3CA NRAS KRAS HRAS BRAF
8
Show member pathways
12.77 RET PIK3CA PAX8 NRAS KRAS HRAS
9
Show member pathways
12.76 PIK3CA NRAS KRAS HRAS BRAF
10
Show member pathways
12.74 PIK3CA NRAS KRAS HRAS BRAF
11 12.7 RET PIK3CA PAX8 NRAS KRAS HRAS
12 12.68 PIK3CA NRAS KRAS HRAS BRAF
13
Show member pathways
12.63 PIK3CA NRAS KRAS HRAS BRAF
14
Show member pathways
12.63 PIK3CA NRAS KRAS HRAS BRAF
15
Show member pathways
12.6 PIK3CA NRAS KRAS HRAS
16 12.56 PIK3CA NRAS KRAS HRAS
17
Show member pathways
12.56 PIK3CA NRAS KRAS HRAS BRAF
18
Show member pathways
12.54 PIK3CA NRAS KRAS HRAS BRAF
19
Show member pathways
12.52 PIK3CA NRAS KRAS HRAS
20
Show member pathways
12.51 PIK3CA NRAS KRAS HRAS
21
Show member pathways
12.48 PIK3CA NRAS KRAS HRAS
22
Show member pathways
12.47 PIK3CA NRAS KRAS HRAS
23
Show member pathways
12.46 NRAS KRAS HRAS BRAF
24
Show member pathways
12.45 PIK3CA NRAS KRAS HRAS
25
Show member pathways
12.44 PIK3CA NRAS KRAS HRAS
26
Show member pathways
12.44 PIK3CA KRAS HRAS BRAF
27
Show member pathways
12.44 PIK3CA NRAS KRAS HRAS BRAF
28
Show member pathways
12.43 PIK3CA NRAS KRAS HRAS
29
Show member pathways
12.4 PIK3CA NRAS KRAS HRAS BRAF
30 12.39 PIK3CA NRAS KRAS HRAS
31
Show member pathways
12.38 NRAS KRAS HRAS BRAF
32
Show member pathways
12.37 PIK3CA NRAS KRAS HRAS
33
Show member pathways
12.34 PIK3CA NRAS KRAS HRAS
34
Show member pathways
12.34 NRAS KRAS HRAS BRAF
35 12.33 PIK3CA NRAS KRAS HRAS
36
Show member pathways
12.3 NRAS KRAS HRAS BRAF
37 12.28 PIK3CA NRAS KRAS HRAS
38 12.28 PIK3CA NRAS KRAS HRAS BRAF
39
Show member pathways
12.27 PIK3CA NRAS KRAS HRAS BRAF
40
Show member pathways
12.27 PIK3CA NRAS KRAS HRAS
41
Show member pathways
12.26 PIK3CA NRAS KRAS HRAS
42
Show member pathways
12.25 PIK3CA NRAS KRAS HRAS BRAF
43
Show member pathways
12.24 NRAS KRAS HRAS BRAF
44 12.22 PIK3CA NRAS KRAS HRAS
45
Show member pathways
12.22 PIK3CA NRAS KRAS HRAS BRAF
46
Show member pathways
12.21 PIK3CA NRAS KRAS HRAS
47
Show member pathways
12.19 NRAS KRAS HRAS BRAF
48
Show member pathways
12.19 PIK3CA NRAS KRAS HRAS
49
Show member pathways
12.19 PIK3CA NRAS KRAS HRAS
50 12.18 PIK3CA NRAS KRAS HRAS

GO Terms for Thyroid Gland Cancer

Biological processes related to Thyroid Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.72 RET KRAS HRAS CDKN2B-AS1 BRAF
2 Ras protein signal transduction GO:0007265 9.58 NRAS KRAS HRAS
3 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.54 NRAS KRAS HRAS
4 negative regulation of neuron apoptotic process GO:0043524 9.46 PIK3CA KRAS HRAS BRAF
5 response to isolation stress GO:0035900 9.26 KRAS HRAS
6 thyroid gland development GO:0030878 9.13 TG PAX8 BRAF
7 MAPK cascade GO:0000165 9.02 RET NRAS KRAS HRAS BRAF

Molecular functions related to Thyroid Gland Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide binding GO:0000166 9.02 RET NRAS KRAS HRAS BRAF

Sources for Thyroid Gland Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....